End Stage Renal Disease Market Size & Growth Forecast 2026–2035, By Segments (Treatment), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

End Stage Renal Disease Market size was estimated at USD 136.21 Billion in 2025 and is projected to grow at a 12.8% CAGR from 2026 to 2035, attaining USD 454.26 Billion by 2035. The industry revenue for 2026 is assessed at USD 151.79 billion.

• Base Year Value (2025): USD 136.21 Billion
• CAGR (2026-2035): 12.8%
• Forecast Year Value (2035): USD 454.26 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

End Stage Renal Disease Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads the market with established dialysis and transplant infrastructure, specialized nephrology services, and organized treatment pathways that sustain consistent demand for renal care.
  • Asia Pacific is projected to expand at a 14.34% CAGR as dialysis access improves, renal care capacity increases, and more patients enter formal long-term treatment pathways.

• Segment Momentum:

  • Dialysis accounted for 74.4% of the market in 2025 because it remains the most established and widely accessible long-term renal replacement therapy for patients requiring ongoing disease management.
  • Dialysis is also the fastest-growing treatment segment as the expanding patient population continues to require accessible, recurring renal replacement therapy delivered through established care pathways.

• Market Expansion Drivers:

  • Rising prevalence of diabetes and hypertension increasing long-term dialysis and renal care demand.
  • Technological advancements in dialysis equipment improving treatment accessibility and patient outcomes.
  • Expanding home dialysis adoption strengthening decentralized renal care infrastructure globally.

• Leading Market Participants:

  Major players in the end stage renal disease market include Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (United States), Nipro Corporation (Japan), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany), Becton Dickinson and Company (United States), Asahi Kasei Medical Co., Ltd. (Japan), Nikkiso Co., Ltd. (Japan), JMS Co., Ltd. (Japan), DaVita Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 136.21 Billion
  • Projected Market Size: USD 454.26 Billion by 2035
  • Growth Forecasts: 12.8% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Dialysis (Treatment)
  • Emerging Opportunity Segment: Dialysis (Treatment)

Market Growth Drivers and Industry Trends

Rising prevalence of diabetes and hypertension increasing long-term dialysis and renal care demand

The growing burden of diabetes and hypertension is steadily enlarging the patient pool progressing to kidney failure, which directly reinforces demand in the end stage renal disease market for dialysis services, vascular access products, monitoring, and long-term renal care management. In practice, this driver increases the flow of patients from chronic kidney disease into sustained treatment pathways that require recurring therapy rather than one-time intervention, giving providers and manufacturers greater visibility into utilization patterns and supporting capacity expansion in dialysis networks, nephrology services, and associated consumables.

Technological advancements in dialysis equipment improving treatment accessibility and patient outcomes

Advances in dialysis equipment are reshaping treatment delivery in the end stage renal disease market by making therapy more efficient, easier to administer, and better suited to varied care settings. Improved machine design, monitoring capabilities, and treatment precision influence provider purchasing decisions because they can reduce treatment complications, support more individualized care, and help facilities manage patients with greater consistency, while also increasing market adoption in regions where older infrastructure or operational complexity previously limited access to regular dialysis.

Expanding home dialysis adoption strengthening decentralized renal care infrastructure globally

The shift toward home-based therapy is changing care models in the end stage renal disease market by moving a portion of treatment demand away from centralized dialysis centers and into remote, patient-managed settings. This transition drives demand for compact equipment, training services, digital monitoring tools, and logistics systems for consumables delivery, while encouraging health systems and providers to invest in decentralized renal care pathways that improve scheduling flexibility and broaden access for patients who face capacity constraints or travel burdens tied to in-center treatment.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing prevalence of end-stage renal disease	4.50%	Short term (≤ 2 yrs)	North America, Europe (spillover: Asia Pacific)	High	Fast
Adoption of dialysis and renal care devices	4.00%	Medium term (2–5 yrs)	Europe, Asia Pacific (spillover: North America)	Medium	Moderate
Expansion of renal care centers in emerging markets	4.30%	Long term (5+ yrs)	North America, Europe (spillover: Asia Pacific)	Medium	Slow
Rising prevalence of diabetes and hypertension increasing long-term dialysis and renal care demand	2.50%	High	North America, Asia Pacific	High	Near Term
Technological advancements in dialysis equipment improving treatment accessibility and patient outcomes	2.10%	High	North America, Europe, Asia Pacific	High	Mid Term
Expanding home dialysis adoption strengthening decentralized renal care infrastructure globally	1.70%	High	North America, Europe	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the end stage renal disease market, supported by its established dialysis and transplant care infrastructure, broad availability of specialized nephrology services, and higher treatment access across hospital and outpatient settings. The region’s leadership is aided by the routine management of advanced kidney disease through organized care pathways, where patients move through diagnosis, long-term dialysis, monitoring, and transplant evaluation within well-developed clinical networks. This practical depth of care delivery sustains high treatment volumes and consistent demand for related therapies and services.

Asia Pacific is projected to expand at a 14.34% CAGR over the forecast period, with growth in the end stage renal disease market being propelled by increasing treatment adoption and the gradual expansion of renal care capacity across the region. Momentum is building as more patients gain access to dialysis services, healthcare systems widen their ability to manage chronic kidney disease progression, and providers invest in facilities capable of handling rising case loads. As access improves in practice, more patients enter formal treatment pathways earlier and remain within managed care systems longer, accelerating regional market growth.

Key Country Insights

United States

Advanced Renal Care

The U.S. prioritizes integrated dialysis services, home-based treatment expansion, and improved patient monitoring for end stage renal disease. Healthcare providers in the U.S. continue investing in digital care pathways and innovative renal therapies to enhance long-term patient management.

Japan

Home Dialysis Evaluation

Japan continues refining renal care through efficient dialysis delivery and evaluation of home-based treatment options. Healthcare institutions in Japan emphasize treatment consistency, patient safety, and technology-supported disease management for individuals with end stage renal disease.

South Korea

Digital Care Integration

South Korea integrates digital health solutions with dialysis services to strengthen long-term management of end stage renal disease. Providers in South Korea are expanding remote monitoring capabilities and optimizing hospital workflows to improve continuity of patient care.

Germany

Precision Treatment Pathways

Germany focuses on high-quality dialysis infrastructure and coordinated nephrology care for patients with end stage renal disease. Clinical providers in Germany are adopting advanced monitoring technologies and personalized treatment approaches to improve therapy efficiency and patient outcomes.

France

Coordinated Patient Management

France prioritizes multidisciplinary renal care supported by structured healthcare networks and standardized treatment pathways. Healthcare providers across France focus on improving patient access, treatment quality, and coordinated monitoring for individuals living with end stage renal disease.

Italy

Clinical Service Modernization

Italy continues modernizing dialysis facilities and expanding access to specialized nephrology services for end stage renal disease. The Italian healthcare system supports technology adoption and coordinated clinical management to improve treatment efficiency and patient experience.

Segment Leadership and Growth Trends

  Treatment Segment Analysis: Dialysis (Largest & Fastest-Growing Segment)

Within the end stage renal disease market, dialysis accounted for a 74.4% share in 2025, reflecting its central role in routine disease management and its continued expansion across the treatment segment. Its leadership is maintained through the fact that dialysis remains the most widely used and operationally established treatment pathway for patients requiring ongoing renal replacement therapy, especially where long-term, repeatable care delivery is essential. The same practical dependence is also driving its faster growth in the end stage renal disease market, as demand continues to build around accessible, recurring treatment support for a growing patient base that needs consistent intervention rather than limited or episodic care.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Treatment	Transplant, Dialysis	Dialysis	Dialysis

Competitive Landscape and Market Positioning

Prominent players in the end stage renal disease market:

1. Fresenius Medical Care AG & Co. KGaA (Germany)

2. Baxter International Inc. (United States)

3. Nipro Corporation (Japan)

4. Medtronic plc (Ireland)

5. B. Braun Melsungen AG (Germany)

6. Becton Dickinson and Company (United States)

7. Asahi Kasei Medical Co. Ltd. (Japan)

8. Nikkiso Co. Ltd. (Japan)

9. JMS Co. Ltd. (Japan)

10. DaVita Inc. (United States)

Growing demand for patient-centered renal care is transforming the end stage renal disease market, with increasing adoption of home-based therapies, digital health monitoring, and integrated treatment approaches. Technological innovation continues to improve treatment accessibility and long-term disease management.

Industry Development/News

Company Name	Date	Key Development
SERB Pharma	May-26	SERB Pharma has acquired the exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union and MENA regions from Hansa Biopharma for €115 million. This acquisition strategically expands access to desensitization therapy for highly sensitized patients awaiting kidney transplants, addressing a critical unmet need in renal care by facilitating transplants for patients with previously limited options.
eGenesis	Oct-24	eGenesis secured $191 million in Series D funding to accelerate the development of genetically engineered, human-compatible porcine kidneys. The investment supports the advancement of its lead candidate, EGEN-2784, toward first-in-human clinical trials. This development represents a significant potential breakthrough in alleviating the global organ shortage, which remains a primary barrier to improved outcomes in end-stage renal disease treatment.
Hansa Biopharma	Sep-25	Hansa Biopharma announced positive topline results from the U.S. Phase 3 ConfIdeS trial of imlifidase, demonstrating superior kidney function at 12 months in highly sensitized patients. The statistically significant findings validate the efficacy of imlifidase as a desensitization therapy, strengthening the company's regulatory path toward FDA approval and potentially transforming the standard of care for patients with high immunological barriers to transplantation.
Centers for Medicare & Medicaid Services (CMS)	May-25	CMS launched a restructured Kidney Care Choices (KCC) Model to incentivize value-based care and increase adoption of home dialysis and kidney transplantation. By shifting reimbursement strategies, the model aims to improve clinical outcomes and operational efficiency within the nephrology value chain, pressuring providers to optimize patient management and reduce long-term costs associated with conventional in-center hemodialysis.
Montefiore Einstein	Aug-25	Montefiore Einstein successfully implemented advanced robotic surgical techniques for kidney transplantation, specifically targeting high-risk and obese ESRD patients. This expansion of surgical capability addresses existing clinical barriers to transplantation, allowing a broader patient population to become eligible for donor organs and signaling a shift in clinical practice toward more minimally invasive and accessible transplant surgery.
Renvio	Sep-25	Renvio partnered with Klinrisk to integrate predictive artificial intelligence into clinical renal care workflows. The platform provides real-time risk assessment for hospitalization and treatment complications directly within existing electronic medical record systems. This digital transformation effort allows dialysis clinics to move from reactive treatment to proactive care management, potentially reducing hospitalizations and improving operational efficiency in ESRD service delivery.
Seoul National University	Apr-25	Researchers at Seoul National University have developed a compact, portable artificial kidney utilizing advanced peritoneal dialysis technology. This innovation aims to enable broader home-based renal replacement therapy by reducing the logistical and mechanical burdens associated with traditional dialysis equipment, representing a significant step toward improving patient autonomy and quality of life for those with end-stage renal disease.